Eris Lifesciences reports Q2FY26 financial results

Eris Lifesciences reports Q2FY26 financial results as per its board meeting outcome. The company has filed its financial results for the quarter ended September 30, 2026, with the exchange. Key performance metrics including revenue and net profit will be closely watched by traders for guidance on F&O positions. ₹ figures and margin trends may influence near-term trading sentiment.

📊 STOCKS: $ERIS | 🏢 SECTOR: Pharma | #HIGHIMPACT #ErisLifesciences